Corsair Pharma
Signal active
Organization
Contact Information
Overview
N/A
About
Industries
Manufacturing, Therapeutics, Dietary Supplements
Founded
2014
Employees
11-50
Headquarters locations
Sunnyvale, California, United States, North America
Social
Profile Resume
Corsair Pharma headquartered in United States, North America, operates in the Manufacturing, Therapeutics, Dietary Supplements sector. The company focuses on Manufacturing and has secured $276.0M in funding across 12 round(s). With a team of 11-50 employees, Corsair Pharma is actively contributing to advancements in Manufacturing. Their latest funding round, Series B - Corsair Pharma, raised $23.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
1
Investors
5
Lead Investors
0
Total Funding Amount
$23.0M
Details
1
Corsair Pharma has raised a total of $23.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2023 | Early Stage Venture | 23.0M |
Investors
Corsair Pharma is funded by 8 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Junson Capital | - | FUNDING ROUND - Junson Capital | 23.0M |
| Primavera Capital Group | - | FUNDING ROUND - Primavera Capital Group | 23.0M |
| Corsair Pharma | - | FUNDING ROUND - Corsair Pharma | 23.0M |
| Plaisance Capital Management | - | FUNDING ROUND - Plaisance Capital Management | 23.0M |
Recent Activity
News
Dec 11, 2023
Corsair Pharma Announces Appointment of George W. Mahaffey as Chief Executive Officer
News
Sep 25, 2023
Corsair moving to test treprostinil skin patch in treating PAH |...
News
Sep 25, 2023
Pulmonary Hypertension News - Corsair moving to test treprostinil skin patch in treating PAH |...
News
Sep 20, 2023
Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension
News
Sep 20, 2023
Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension
News
Sep 20, 2023
GlobeNewswire - Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension